Alpelisib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ALPELISIB |
|---|---|
| Type | Drug |
| Aliases | PiqrayАлпелісіб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | PI3K-alpha-selective inhibitor |
|---|---|
| Mechanism | Selective inhibitor of PI3K-alpha (p110α isoform). Active in PIK3CA-mutant HR+/HER2- metastatic — combined with fulvestrant per SOLAR-1. |
| Typical dosing | 300 mg PO once daily with food + fulvestrant standard dosing. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
SOLAR-1: PIK3CA-mutant HR+/HER2- metastatic post-AI. Pre-treatment PIK3CA testing (tissue or ctDNA) required. Hyperglycemia management dominant clinical workflow burden.
Used By
Regimens
REG-ALPELISIB-FULVESTRANT-BREAST- Alpelisib + fulvestrant (HR+/HER2- PIK3CA-mutant metastatic post-AI/CDK4/6i)